KalVista:HC Wainwright Raises PT to $27, Maintains Buy Rating

KalVista:HC Wainwright Raises PT to $27, Maintains Buy Rating

H.C. Wainwright analyst Andrew Fein has raised the price target for KalVista Pharmaceuticals Inc. (NASDAQ: KALV) to $27.00, while maintaining a "Buy" rating on the stock. The update comes amidst a wave of positive analyst sentiment surrounding the company's recently approved drug, Ekterly (sebetralstat), which is set to launch in the U.S. with a wholesale acquisition cost of approximately $16,720 per dose [1].

The FDA approval of Ekterly, the first oral on-demand treatment for hereditary angioedema (HAE) attacks, has sparked optimism among analysts. Stifel, for instance, reiterated its "Buy" rating with a $39.00 price target, citing Ekterly's favorable market positioning and potential for rapid adoption [3]. Leerink Partners and BofA Securities have also raised their price targets, reflecting a growing consensus on KalVista's stock potential.

Fein's revised estimate for KalVista's Q4 2025 EPS is $0.35 per share, up from the previous estimate of $0.84. The analyst also issued estimates for the company's full-year earnings for 2026 to 2030, projecting a significant increase in earnings over the next several years [4].

KalVista's strong financial position, with more cash than debt and a healthy current ratio of 10.44, further supports the bullish outlook. The company's recent announcements, including the FDA approval of Ekterly and the establishment of KalVista Cares, a patient support program, have bolstered investor confidence [1].

Despite the positive developments, KalVista faces challenges such as rapid cash burn and the potential impact of generic competition in the HAE market. However, the company's strategic focus on market expansion in Europe, Germany, Japan, and the United Kingdom, as well as its ongoing clinical studies, positions it well for future growth [1].

References:
[1] https://za.investing.com/news/analyst-ratings/kalvista-stock-price-target-raised-to-27-from-19-at-jmp-on-ekterly-pricing-93CH-3781239
[2] https://www.streetinsider.com/Analyst+PT+Change/Kalvista+Pharmaceuticals+Inc+%28KALV%29+PT+Raised+to+%2427+at+H.C.+Wainwright/25025944.html
[3] https://in.investing.com/news/analyst-ratings/kalvista-stock-jumps-as-stifel-reiterates-buy-rating-on-ekterly-approval-93CH-4902394
[4] https://www.marketbeat.com/instant-alerts/hc-wainwright-issues-positive-forecast-for-kalv-earnings-2025-07-10/